Foresite Capital Opportunity Fund V, L.p. - Net Worth and Insider Trading
Foresite Capital Opportunity Fund V, L.p. Net Worth
The estimated net worth of Foresite Capital Opportunity Fund V, L.p. is at least $19 Million dollars as of 2024-04-28. Foresite Capital Opportunity Fund V, L.p. is the 10% Owner of Pardes Biosciences Inc and owns about 8,773,134 shares of Pardes Biosciences Inc (PRDS) stock worth over $19 Million. Details can be seen in Foresite Capital Opportunity Fund V, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Foresite Capital Opportunity Fund V, L.p. has not made any transactions after 2023-04-05 and currently still holds the listed stock(s).
Transaction Summary of Foresite Capital Opportunity Fund V, L.p.
Foresite Capital Opportunity Fund V, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Foresite Capital Opportunity Fund V, L.p. owns 4 companies in total, including Kinnate Biopharma Inc (KNTE) , Disc Medicine Inc (IRON) , and Pardes Biosciences Inc (PRDS) among others .
Insider Ownership Summary of Foresite Capital Opportunity Fund V, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KNTE | Kinnate Biopharma Inc | 2020-12-02 | 10 percent owner |
| IRON | Disc Medicine Inc | 2020-10-19 | 10 percent owner |
| PRDS | Pardes Biosciences Inc | 2023-04-05 | 10 percent owner |
| THRX | Theseus Pharmaceuticals Inc | 2022-06-09 | 10 percent owner |
Foresite Capital Opportunity Fund V, L.p. Latest Holdings Summary
Foresite Capital Opportunity Fund V, L.p. currently owns a total of 1 stock. Foresite Capital Opportunity Fund V, L.p. owns 8,773,134 shares of Pardes Biosciences Inc (PRDS) as of April 5, 2023, with a value of $19 Million.
Latest Holdings of Foresite Capital Opportunity Fund V, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PRDS | Pardes Biosciences Inc | 2023-04-05 | 8,773,134 | 2.16 | 18,949,969 |
Holding Weightings of Foresite Capital Opportunity Fund V, L.p.
Foresite Capital Opportunity Fund V, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Foresite Capital Opportunity Fund V, L.p. has made a total of 1 transactions in Pardes Biosciences Inc (PRDS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Pardes Biosciences Inc is the acquisition of 773,952 shares on April 5, 2023, which cost Foresite Capital Opportunity Fund V, L.p. around $1 Million.
Insider Trading History of Foresite Capital Opportunity Fund V, L.p.
- 1
Foresite Capital Opportunity Fund V, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Foresite Capital Opportunity Fund V, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Foresite Capital Opportunity Fund V, L.p. is 19.48%. GuruFocus also compares Foresite Capital Opportunity Fund V, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Foresite Capital Opportunity Fund V, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Foresite Capital Opportunity Fund V, L.p.'s insider trading performs compared to the benchmark.
Performance of Foresite Capital Opportunity Fund V, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 23.38 | 19.48 | ||||
| Relative Return to S&P 500(%) | 22.26 | 10.77 |
Foresite Capital Opportunity Fund V, L.p. Ownership Network
Ownership Network List of Foresite Capital Opportunity Fund V, L.p.
Ownership Network Relation of Foresite Capital Opportunity Fund V, L.p.
Foresite Capital Opportunity Fund V, L.p. Owned Company Details
What does Kinnate Biopharma Inc do?
Who are the key executives at Kinnate Biopharma Inc?
Foresite Capital Opportunity Fund V, L.p. is the 10 percent owner of Kinnate Biopharma Inc. Other key executives at Kinnate Biopharma Inc include director & 10 percent owner James B. Tananbaum , 10 percent owner Foresite Capital Fund Iv, L.p. , and director & 10 percent owner Orbimed Capital Gp Viii Llc .
Kinnate Biopharma Inc (KNTE) Insider Trades Summary
Over the past 18 months, Foresite Capital Opportunity Fund V, L.p. made no insider transaction in Kinnate Biopharma Inc (KNTE). Other recent insider transactions involving Kinnate Biopharma Inc (KNTE) include a net purchase of 2,866,100 shares made by Carl L Gordon , a net purchase of 2,866,100 shares made by Orbimed Advisors Llc , and a net purchase of 1,780,000 shares made by James B. Tananbaum .
In summary, during the past 3 months, insiders sold 0 shares of Kinnate Biopharma Inc (KNTE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kinnate Biopharma Inc (KNTE) were sold and 9,292,200 shares were bought by its insiders, resulting in a net purchase of 9,292,200 shares.
Kinnate Biopharma Inc (KNTE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Kinnate Biopharma Inc Insider Transactions
Foresite Capital Opportunity Fund V, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Foresite Capital Opportunity Fund V, L.p.. You might contact Foresite Capital Opportunity Fund V, L.p. via mailing address: 600 Montgomery Street, Suite 4500, San Francisco Ca 94111.
Discussions on Foresite Capital Opportunity Fund V, L.p.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
